Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action

References

• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• WilliamsRRigbyASAireyMRobinsonMFordHMultiple sclerosis: its epidemiological, genetic, and health care impactJ Epidemiol Community Health19954965635698596089
   PubMed Web of Science ®Google Scholar
• CompstonAColesAMultiple sclerosisLancet200235993131221123111955556
   PubMed Web of Science ®Google Scholar
• CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
   PubMed Web of Science ®Google Scholar
• KeeganBMNoseworthyJHMultiple sclerosisAnn Rev Medic200253285302
   PubMed Web of Science ®Google Scholar
• Koch-HenriksenNThe Danish Multiple Sclerosis Registry: a 50-year follow-upMult Scler19995429329610467392
   PubMed Web of Science ®Google Scholar
• MayrWTPittockSJMcClellandRLJorgensenNWNoseworthyJHRodriguezMIncidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000Neurology200361101373137714638958
   PubMed Web of Science ®Google Scholar
• HawkinsSAMcDonnellGVBenign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factorsJ Neurol Neurosurg Psychiatry199967214815210406979
   PubMed Web of Science ®Google Scholar
• WhitacreCCReingoldSCO’LooneyPAA gender gap in autoimmunity: Task Force on Gender, Multiple Sclerosis and AutoimmunityScience199928354061277127810084932
   PubMed Web of Science ®Google Scholar
• OrtonSMHerreraBMYeeIMSex ratio of multiple sclerosis in Canada: a longitudinal studyLancet Neurol200651193293617052660
   PubMed Web of Science ®Google Scholar
• KisterIChamotESalterARCutterGRBaconTEHerbertJDisability in multiple sclerosis: a reference for patients and cliniciansNeurology201380111018102423427319
   PubMed Web of Science ®Google Scholar
• SadovnickADEbersGCWilsonRWPatyDWLife expectancy in patients attending multiple sclerosis clinicsNeurology19924259919941579256
   PubMed Web of Science ®Google Scholar
• CharcotJMHistologie de la sclerose en plaquesGaz Hop Civ Mil Empire Ottoman186841554555
   Google Scholar
• PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol201169229230221387374
   PubMed Web of Science ®Google Scholar
• StangelMFredriksonSMeinlEPetzoldAStuveOTumaniHThe utility of cerebrospinal fluid analysis in patients with multiple sclerosisNat Rev Neurol20139526727623528543
   PubMed Web of Science ®Google Scholar
• KuenzBDeisenhammerFBergerTReindlMDiagnostic biomarkers in multiple sclerosisExpert Opinion Medical Diagn200712225233
   PubMedGoogle Scholar
• KatsavosSAnagnostouliMBiomarkers in multiple sclerosis: an up-to-date overviewMult Scler Int2013201334050823401777
   PubMedGoogle Scholar
• LeoneMABarizzoneNEspositoFAssociation of genetic markers with CSF oligoclonal bands in multiple sclerosis patientsPloS One201386e6440823785401
   PubMed Web of Science ®Google Scholar
• RudickRAThe elusive biomarker for personalized medicine in multiple sclerosis: the search continuesNeurology201279649849922573625
   PubMed Web of Science ®Google Scholar
• OberwahrenbrockTSchipplingSRingelsteinMRetinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomographyMult Scler Int2012201253030522888431
   PubMedGoogle Scholar
• VukusicSConfavreuxCPrimary and secondary progressive multiple sclerosisJ Neurol Sci2003206215315512559503
   PubMed Web of Science ®Google Scholar
• HagmanSRaunioMRossiMDastidarPElovaaraIDisease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up studyJ Neuroimmunol20112341–214114721397339
   PubMed Web of Science ®Google Scholar
• FreedmanMSSelchenDArnoldDLTreatment optimization in MS: Canadian MS Working Group updated recommendationsCan J Neurol Sci201340330732323603165
   PubMed Web of Science ®Google Scholar
• KieseierBCWiendlHHemmerBHartungHPTreatment and treatment trials in multiple sclerosisCurr Opin Neurol200720328629317495622
   PubMed Web of Science ®Google Scholar
• SpainRICameronMHBourdetteDRecent developments in multiple sclerosis therapeuticsBMC Med200977419968863
   PubMed Web of Science ®Google Scholar
• FilippiniGBrusaferriFSibleyWACorticosteroids or ACTH for acute exacerbations in multiple sclerosisCochrane Database Syst Rev20004CD00133111034713
   PubMedGoogle Scholar
• RudickRACohenJAWeinstock-GuttmanBKinkelRPRansohoffRMManagement of multiple sclerosisN Engl J Med199733722160416119371858
   PubMed Web of Science ®Google Scholar
• BerkovichRTreatment of acute relapses in multiple sclerosisNeurotherapeutics20131019710523229226
   PubMed Web of Science ®Google Scholar
• BurtonJMO’ConnorPWHoholMBeyeneJOral versus intravenous steroids for treatment of relapses in multiple sclerosisCochrane Database Syst Rev201212CD00692123235634
   PubMed Web of Science ®Google Scholar
• MyhrKMMellgrenSICorticosteroids in the treatment of multiple sclerosisActa Neurologica Scand Suppl20091897380
   Google Scholar
• LassmannHPathology and disease mechanisms in different stages of multiple sclerosisJ Neurol Sci Epub622013
   Web of Science ®Google Scholar
• BøLEsiriMEvangelouNKuhlmannTDemyelination and remyelination in multiple sclerosisDuncanIDFranklinRJMMyelin Repair and Neuroprotection in Multiple SclerosisNew YorkSpringer20132345
   Google Scholar
• CraytonHHeymanRARossmanHSA multimodal approach to managing the symptoms of multiple sclerosisNeurology20046311 Suppl 5S12S1815596731
   PubMed Web of Science ®Google Scholar
• KurtzkeJFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology19833311144414526685237
   PubMed Web of Science ®Google Scholar
• Weinstock-GuttmanBRansohoffRMKinkelRPRudickRAThe interferons: biological effects, mechanisms of action, and use in multiple sclerosisAnn Neurol19953717157529476
   PubMed Web of Science ®Google Scholar
• LinLBetaseronDev Biol Stand199896971049890522
   PubMedGoogle Scholar
• WeberFJanovskajaJPolakTPoserSRieckmannPEffect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1bNeurology19995251069107110102432
   PubMed Web of Science ®Google Scholar
• RudickRARansohoffRMLeeJCIn vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosisNeurology1998505129413009595977
   PubMed Web of Science ®Google Scholar
• YongVWChabotSStuveOWilliamsGInterferon beta in the treatment of multiple sclerosis: mechanisms of actionNeurology19985136826899748010
   PubMed Web of Science ®Google Scholar
• KieseierBCThe mechanism of action of interferon-beta in relapsing multiple sclerosisCNS Drugs201125649150221649449
   PubMed Web of Science ®Google Scholar
• PatyDWLiDKInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study GroupNeurology19934346626678469319
   PubMed Web of Science ®Google Scholar
• [No authors listed]Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study GroupNeurology19934346556618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosisAnn Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• FernandezOAntiquedadAArbizuTTreatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trialMult Scler19951Suppl 1S67S699345404
   PubMedGoogle Scholar
• PonomarenkoNADurovaOMVorobievIIAutoantibodies to myelin basic protein catalyze site-specific degradation of their antigenProc Natl Acad Sci U S A2006103228128616387849
   PubMed Web of Science ®Google Scholar
• PonomarenkoNADurovaOMVorobievIICatalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scaleImmunol Lett20061031455016297986
   PubMed Web of Science ®Google Scholar
• ValliASetteAKapposLBinding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patientsJ Clin Invest19939126166287679413
   PubMed Web of Science ®Google Scholar
• OtaKMatsuiMMilfordELMackinGAWeinerHLHaflerDAT-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosisNature199034662801831871694970
   PubMed Web of Science ®Google Scholar
• WolinskyJSCopolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disabilityNeurology1995457124512477617175
   PubMed Web of Science ®Google Scholar
• Fridkis-HareliMTeitelbaumDGurevichEDirect binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells – specificity and promiscuityProc Natl Acad Sci U S A19949111487248767515181
   PubMed Web of Science ®Google Scholar
• GranBTranquillLRChenMMechanisms of immunomodulation by glatiramer acetateNeurology200055111704171411113226
   PubMed Web of Science ®Google Scholar
• BergerATh1 and Th2 responses: what are they?BMJ2000321725842410938051
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology1995457126812767617181
   PubMed Web of Science ®Google Scholar
• KorczynADNisipeanuPSafety profile of copolymer 1: analysis of cumulative experience in the United States and IsraelJ Neurol19962434 Suppl 1S23S268965117
   PubMed Web of Science ®Google Scholar
• MunariLLovatiRBoikoATherapy with glatiramer acetate for multiple sclerosisCochrane Database Syst Rev20041CD00467814974077
   PubMedGoogle Scholar
• La MantiaLMunariLMLovatiRGlatiramer acetate for multiple sclerosisCochrane Database Syst Rev20105CD00467820464733
   PubMed Web of Science ®Google Scholar
• YednockTACannonCFritzLCSanchez-MadridFSteinmanLKarinNPrevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrinNature1992356636463661538783
   PubMed Web of Science ®Google Scholar
• LegerOJYednockTATannerLHumanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosisHum Antibodies1997813169265500
   PubMedGoogle Scholar
• KentSJKarlikSJRiceGPHornerHCA monoclonal antibody to alpha 4-integrin reverses the MR-detectable signs of experimental allergic encephalomyelitis in the guinea pigJ Magn Reson Imaging1995555355408574037
   PubMed Web of Science ®Google Scholar
• MillerDHKhanOASheremataWAA controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med20033481152312510038
   PubMed Web of Science ®Google Scholar
• KentSJKarlikSJCannonCA monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitisJ Neuroimmunol19955811107730443
   PubMed Web of Science ®Google Scholar
• ElicesMJNatalizumab. Elan/BiogenCurr Opin Investig Drugs200341113541362
   PubMedGoogle Scholar
• BauerMBrakebuschCCoisneCBeta1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunityProc Natl Acad Sci U S A200910661920192519179279
   PubMed Web of Science ®Google Scholar
• CoisneCMaoWEngelhardtBCutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosisJ Immunol2009182105909591319414741
   PubMed Web of Science ®Google Scholar
• SheremataWAVollmerTLStoneLAWillmer-HulmeAJKollerMA safety and pharmacokinetic study of intravenous natalizumab in patients with MSNeurology19995251072107410102433
   PubMed Web of Science ®Google Scholar
• O’ConnorPMillerDRiesterKRelapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosisMult Scler200511556857216193895
   PubMed Web of Science ®Google Scholar
• SheremataWAMinagarAAlexanderJSVollmerTThe role of alpha-4 integrin in the aetiology of multiple sclerosis: current knowledge and therapeutic implicationsCNS Drugs2005191190992216268663
   PubMed Web of Science ®Google Scholar
• O’ConnorPNatalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosisExpert Opin Biol Ther20077112313617150024
   PubMed Web of Science ®Google Scholar
• MillerDHSoonDFernandoKTMRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSNeurology200768171390140117452584
   PubMed Web of Science ®Google Scholar
• RudickRAMillerDHassSHealth-related quality of life in multiple sclerosis: effects of natalizumabAnn Neurol200762433534617696126
   PubMed Web of Science ®Google Scholar
• BalcerLJGalettaSLCalabresiPANatalizumab reduces visual loss in patients with relapsing multiple sclerosisNeurology200768161299130417438220
   PubMed Web of Science ®Google Scholar
• PhillipsJTGiovannoniGLublinFDSustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosisMult Scler201117897097921421809
   PubMed Web of Science ®Google Scholar
• Weinstock-GuttmanBGalettaSLGiovannoniGAdditional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MSJ Neurol2012259589890522008873
   PubMed Web of Science ®Google Scholar
• CadavidDJurgensenSLeeSImpact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosisPloS One201381e5329723308186
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPANatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med322006354991192316510745
   PubMed Web of Science ®Google Scholar
• Biogen IdecTysabri (natalizumab): benefit/risk update and PML risk stratification2013 Available from: http://www.slideshare.net/gavingiovannoni/natalizumanAccessed September 17, 2013
   Google Scholar
• BloomgrenGRichmanSHotermansCRisk of natalizumab-associated progressive multifocal leukoencephalopathyN Engl J Med2012366201870188022591293
   PubMed Web of Science ®Google Scholar
• PlavinaTSubramanyamMBloomgrenGUse of JC virus antibody index to stratify risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosisPoster presented at: 27th Annual Meeting of the CMSC and the Fifth Cooperative Meeting of the CMSC-ACTRIMSMay 29–June 1, 2013Orlando, FL
   Google Scholar
• SchwabNSchneider-HohendorfTPosevitzVL-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNeurology2013811086587123925765
   PubMed Web of Science ®Google Scholar
• FoleyJFNatalizumab related PML: an evolving risk stratification paradigmPoster presented at: American Academy of Neurology 2013 Annual MeetingMarch 16–23, 2013San Diego, CA
   Google Scholar
• GonsetteRENeurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicityJ Neurol Sci20082741–2485318684473
   PubMed Web of Science ®Google Scholar
• BrosnanCFCannellaBBattistiniLRaineCSCytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen speciesNeurology1995456 Suppl 6S16S217540265
   PubMed Web of Science ®Google Scholar
• WierinckxABrevéJMercierDSchultzbergMDrukarchBVan DamAMDetoxication enzyme inducers modify cytokine production in rat mixed glial cellsJ Neuroimmunol20051661–213214315993952
   PubMed Web of Science ®Google Scholar
• MillerEWachowiczBMajsterekIAdvances in antioxidative therapy of multiple sclerosisCurrent medicinal chemistry Epub6252013
   Web of Science ®Google Scholar
• BogdanCNitric oxide and the immune responseNat Immunol200121090791611577346
   PubMed Web of Science ®Google Scholar
• NathanCShilohMUReactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogensProc Natl Acad Sci U S A200097168841884810922044
   PubMed Web of Science ®Google Scholar
• HibbsJBJrTaintorRRVavrinZRachlinEMNitric oxide: a cytotoxic activated macrophage effector moleculeBiochem Biophys Res Commun1988157187943196352
   PubMed Web of Science ®Google Scholar
• SmithKJKapoorRFeltsPADemyelination: the role of reactive oxygen and nitrogen speciesBrain Pathol19999169929989453
   PubMed Web of Science ®Google Scholar
• SuKGBankerGBourdetteDForteMAxonal degeneration in multiple sclerosis: the mitochondrial hypothesisCurr Neurol Neurosci Rep20099541141719664372
   PubMed Web of Science ®Google Scholar
• AlbrechtPBouchachiaIGoebelsNEffects of dimethyl fumarate on neuroprotection and immunomodulationJ Neuroinflammation2012916322769044
   PubMed Web of Science ®Google Scholar
• SchillingSGoelzSLinkerRLuehderFGoldRFumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltrationClin Exp Immunol2006145110110716792679
   PubMed Web of Science ®Google Scholar
• VandermeerenMJanssensSBorgersMGeysenJDimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cellsBiochem Biophys Res Commun1997234119239168952
   PubMed Web of Science ®Google Scholar
• LinkerRALeeDHRyanSFumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain2011134367869221354971
   PubMed Web of Science ®Google Scholar
• KohenRNyskaAOxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantificationToxicol Pathol200230662065012512863
   PubMed Web of Science ®Google Scholar
• ScannevinRHChollateSJungMYFumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathwayJ Pharmacol Exp Ther2012341127428422267202
   PubMed Web of Science ®Google Scholar
• SchimrigkSBruneNHellwigKOral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot studyEur J Neurol200613660461016796584
   PubMed Web of Science ®Google Scholar
• WakkeeMThioHBDrug evaluation: BG-12, an immunomodulatory dimethylfumarateCurr Opinion Investig Drugs2007811955962
   PubMedGoogle Scholar
• KapposLGoldRMillerDHEfficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837296481463147218970976
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisN Engl J Med2012367121087109722992072
   PubMed Web of Science ®Google Scholar
• HutchinsonMFoxRJMillerDHClinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM studyJournal of Neurology201326092286229623749293
   PubMed Web of Science ®Google Scholar
• ErmisUWeisJSchulzJBPML in a patient treated with fumaric acidN Engl J Med2013368171657165823614603
   PubMed Web of Science ®Google Scholar
• van OostenBWKillesteinJBarkhofFPolmanCHWattjesMPPML in a patient treated with dimethyl fumarate from a compounding pharmacyN Engl J Med2013368171658165923614604
   PubMed Web of Science ®Google Scholar
• SweetserMTDawsonKTBozicCManufacturer’s response to case reports of PMLN Engl J Med2013368171659166123614605
   PubMed Web of Science ®Google Scholar
• ZeydaMPoglitschMGeyereggerRDisruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formationArthritis Rheum20055292730273916142756
   PubMed Web of Science ®Google Scholar
• O’ConnorPWLiDFreedmanMSA Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology200666689490016567708
   PubMed Web of Science ®Google Scholar
• WarnkeCMeyer zu HörsteGHartungHPStüveOKieseierBCReview of teriflunomide and its potential in the treatment of multiple sclerosisNeuropsychiatr Dis Treat2009533334019557143
   PubMed Web of Science ®Google Scholar
• FoxRIHerrmannMLFrangouCGMechanism of action for leflunomide in rheumatoid arthritisClin Immunol199993319820810600330
   PubMed Web of Science ®Google Scholar
• HerrmannMLSchleyerbachRKirschbaumBJLeflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseasesImmunopharmacology2000472–327328910878294
   PubMed Web of Science ®Google Scholar
• OhJO’ConnorPWTeriflunomide for the treatment of multiple sclerosisSemin Neurol2013331455523709212
   PubMed Web of Science ®Google Scholar
• Iglesias-BregnaDHanakSJiZEffects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitisJ Pharmacol Exp Ther Epub Jul26
   Google Scholar
• MerrillJEHanakSPuSFTeriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitisJ Neurol200925618910319169851
   PubMed Web of Science ®Google Scholar
• SanofiPhase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (TOPIC) Available from: http://clinicaltrials.gov/show/NCT00622700. Identifier: NCT00622700Accessed September 27, 2013
   Google Scholar
• OlssonTZhiWWHöjebergBAutoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gammaJ Clin Invest19908639819851697609
   PubMed Web of Science ®Google Scholar
• MandalaSHajduRBergstromJAlteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonistsScience2002296556634634911923495
   PubMed Web of Science ®Google Scholar
• YoppACRandolphGJBrombergJSLeukotrienes, sphingolipids, and leukocyte traffickingJ Immunol2003171151012816975
   PubMed Web of Science ®Google Scholar
• O’SullivanCDevKKThe structure and function of the S1P1 receptorTrends Pharmacol Sci201334740141223763867
   PubMed Web of Science ®Google Scholar
• XieJHNomuraNKoprakSLQuackenbushEJForrestMJRosenHSphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cellsJ Immunol200317073662367012646631
   PubMed Web of Science ®Google Scholar
• YanagawaYMasubuchiYChibaKFTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer’s patches by FTY720-induced lymphocyte homingImmunology19989545915949893050
   PubMed Web of Science ®Google Scholar
• YanagawaYSugaharaKKataokaHKawaguchiTMasubuchiYChibaKFTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivoJ Immunol199816011549354999605152
   PubMed Web of Science ®Google Scholar
• ChibaKYanagawaYMasubuchiYFTY720, a novel immuno-suppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homingJ Immunol199816010503750449590253
   PubMed Web of Science ®Google Scholar
• FujinoMFuneshimaNKitazawaYAmelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatmentJ Pharmacol Exp Ther20033051707712649354
   PubMed Web of Science ®Google Scholar
• MironVELudwinSKDarlingtonPJFingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slicesAm J Pathol201017662682269420413685
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
   PubMed Web of Science ®Google Scholar
• LindseyJWHaden-PinneriKMemonNBBujaLMSudden unexpected death on fingolimodMult Scler201218101507150822300970
   PubMed Web of Science ®Google Scholar
• RatchfordJNCostelloKReichDSCalabresiPAVaricella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimodNeurology201279192002200423035072
   PubMed Web of Science ®Google Scholar
• RukovetsOFDA investigates PML in patient taking Gilenya2013 Available from: http://journals.lww.com/neurotodayonline/blog/breakingnews/pages/post.aspx?PostID=240Accessed September 17, 2013
   Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• [No authors listed]Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupLancet19983529139149815049820297
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet201238098561819182823122652
   PubMed Web of Science ®Google Scholar
• ComiGJefferyDKapposLPlacebo-controlled trial of oral laquinimod for multiple sclerosisN Engl J Med2012366111000100922417253
   PubMed Web of Science ®Google Scholar
• GoldRGiovannoniGSelmajKDaclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trialLancet201338198842167217523562009
   PubMed Web of Science ®Google Scholar
• KapposLLiDCalabresiPAOcrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo- controlled, multicentre trialLancet201137898051779178722047971
   PubMed Web of Science ®Google Scholar